61 related articles for article (PubMed ID: 18547158)
1. Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-alpha in patients with renal cell carcinoma.
Van Gool AR; Verkerk R; Fekkes D; Sleijfer S; Bannink M; Kruit WH; van der Holt B; Scharpé S; Eggermont AM; Stoter G; Hengeveld MW
J Interferon Cytokine Res; 2008 May; 28(5):283-6. PubMed ID: 18547158
[TBL] [Abstract][Full Text] [Related]
2. Serum activity of prolyl endopeptidase, but not of dipeptidyl peptidase IV, is decreased by immunotherapy with IFN-alpha in high-risk melanoma patients.
Van Gool AR; Van Ojik HH; Kruit WH; Mulder PG; Fekkes D; Bannink M; Scharpé S; Stoter G; Eggermont AM; Maes M; Verkerk R
J Interferon Cytokine Res; 2004 Jul; 24(7):411-5. PubMed ID: 15296652
[TBL] [Abstract][Full Text] [Related]
3. Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-alpha: course and relationship with psychiatric status.
Van Gool AR; Verkerk R; Fekkes D; Bannink M; Sleijfer S; Kruit WH; van der Holt B; Scharpé S; Eggermont AM; Stoter G; Hengeveld MW
Psychiatry Clin Neurosci; 2008 Oct; 62(5):597-602. PubMed ID: 18950381
[TBL] [Abstract][Full Text] [Related]
4. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.
Capuron L; Ravaud A; Miller AH; Dantzer R
Brain Behav Immun; 2004 May; 18(3):205-13. PubMed ID: 15050647
[TBL] [Abstract][Full Text] [Related]
5. Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated.
Bannink M; Kruit WH; Van Gool AR; Sleijfer S; van der Holt B; Eggermont AM; Stoter G; Hengeveld MW
Psychosomatics; 2008; 49(1):56-63. PubMed ID: 18212177
[TBL] [Abstract][Full Text] [Related]
6. [Depression during interferon therapy in renal cell cancer patients--comparison with chronic hepatitis C patients].
Sakamoto H; Inoue K; Shimada M; Yoshida H; Otsubo T; Miyaoka H; Kamizima K; Ishii M; Mitamura K
Nihon Hinyokika Gakkai Zasshi; 2000 Sep; 91(9):611-7. PubMed ID: 11068424
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
8. Relation of prenephrectomy CD profiles and serum cytokines to the disease outcome and response to IFN-alpha/IL-2 therapy in renal cell carcinoma patients.
Lauerová L; Dusek L; Spurny V; Simicková M; Rovny A; Rejthar A; Kocák I; Kovarík J
Oncol Rep; 2001; 8(3):685-92. PubMed ID: 11295103
[TBL] [Abstract][Full Text] [Related]
9. Type-I interferon receptor expression: its circadian rhythm and downregulation after interferon-alpha administration in peripheral blood cells from renal cancer patients.
Shiba M; Nonomura N; Nakai Y; Nakayama M; Takayama H; Inoue H; Tsujimura A; Nishimura K; Okuyama A
Int J Urol; 2009 Apr; 16(4):356-9. PubMed ID: 19302507
[TBL] [Abstract][Full Text] [Related]
10. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC).
Passalacqua R; Caminiti C; Buti S; Porta C; Camisa R; Braglia L; Tomasello G; Vaglio A; Labianca R; Rondini E; Sabbatini R; Nastasi G; Artioli F; Prati A; Potenzoni M; Pezzuolo D; Oliva E; Alberici F; Buzio C;
J Immunother; 2014; 37(9):440-7. PubMed ID: 25304727
[TBL] [Abstract][Full Text] [Related]
12. Neutrophil number after interferon-alfa treatment is an independent predictive marker of overall survival in metastatic renal cell carcinoma.
Azuma T; Matayoshi Y; Nagase Y; Oshi M
Clin Genitourin Cancer; 2012 Sep; 10(3):180-4. PubMed ID: 22608529
[TBL] [Abstract][Full Text] [Related]
13. Multi-modal treatment of primarily using continuous subcutaneous interferon-alpha injection in combination with surgery and/or radiotherapy.
Maruoka M; Fujimura M; Kawamura K; Suzuki S; Hamano M; Nishikawa Y; Nagayama T
Int J Urol; 2005 May; 12(5):442-8. PubMed ID: 15948742
[TBL] [Abstract][Full Text] [Related]
14. Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level.
Akaza H; Tsukamoto T; Fujioka T; Tomita Y; Kitamura T; Ozono S; Miki T; Naito S; Zembutsu H; Nakamura Y
Jpn J Clin Oncol; 2011 Aug; 41(8):1023-30. PubMed ID: 21642665
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous administration of interferon alpha and gamma in patients with metastatic renal cell carcinoma.
Koga S; Nishikido M; Matsuya F; Kanetake H; Saito Y
Anticancer Res; 1999; 19(6C):5547-50. PubMed ID: 10697614
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2, interferon-alpha and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience.
O'Brien MF; Rea D; Rogers E; Bredin H; Butler M; Grainger R; McDermott TE; Mullins G; O'Brien A; Twomey A; Thornhill J
Eur Urol; 2004 May; 45(5):613-8; discussion 619. PubMed ID: 15082204
[TBL] [Abstract][Full Text] [Related]
17. The effectors of killer activity induced by interferon-alpha and gamma in peripheral blood mononuclear cells.
Sakaguchi M; Kubota S; Nishikido M; Taniguchi K; Inuzuka S; Saito Y; Kanetake H; Koga S
Int J Mol Med; 2002 Sep; 10(3):317-20. PubMed ID: 12165807
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous interleukin-2 and interferon-alpha in metastatic renal cell carcinoma: results of a French regional experience in Languedoc.
Culine S; Iborra F; Mottet N; Avancès C; de Graeve B; Volpé P; Vignoud J; Bringer JP; Marroncle M; Le Pellec L; Ayuso D; Jansen E; Faix A; Rebillard X
Am J Clin Oncol; 2006 Apr; 29(2):148-52. PubMed ID: 16601433
[TBL] [Abstract][Full Text] [Related]
19. Increased prolyl endopeptidase activity in human neoplasia.
Larrinaga G; Perez I; Blanco L; López JI; Andrés L; Etxezarraga C; Santaolalla F; Zabala A; Varona A; Irazusta J
Regul Pept; 2010 Aug; 163(1-3):102-6. PubMed ID: 20362629
[TBL] [Abstract][Full Text] [Related]
20. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma.
Ito N; Eto M; Nakamura E; Takahashi A; Tsukamoto T; Toma H; Nakazawa H; Hirao Y; Uemura H; Kagawa S; Kanayama H; Nose Y; Kinukawa N; Nakamura T; Jinnai N; Seki T; Takamatsu M; Masui Y; Naito S; Ogawa O
J Clin Oncol; 2007 Jul; 25(19):2785-91. PubMed ID: 17602083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]